Valuation: Epigenomics AG

Market Cap 824K 939K 767K 703K 1.32M 90.39M 1.34M 9.1M 3.56M 44.44M 3.52M 3.45M 154M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.79M 13.43M 10.97M 10.06M 18.91M 1.29B 19.2M 130M 50.87M 636M 50.4M 49.31M 2.2B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Current month+8.05%
1 month+8.05%
3 months+0.53%
6 months+4.44%
Current year+4.44%
1 week 0.94
Extreme 0.94
0.94
1 month 0.87
Extreme 0.87
1.4
Current year 0.84
Extreme 0.84
1.55
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
4.2
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Date Insider Type Main position Quantity % Market Cap.
12/29/22 Buy

Chief Financial Officer

2,000 0.0122%
9/7/21 Sell

Director

7,790 0.0637%
2/1/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+2.17%-75.90% 937K
-2.19%-4.26%+139.97%+105.56% 4.62B
-0.18%-2.84%+108.91%+185.51% 3.57B
-2.73%-0.20%+51.67%-32.29% 2.29B
-0.90%+1.56%-30.96%-37.12% 2.09B
-1.25%-6.52%+189.25%+256.77% 1.94B
-4.11%-6.63%+149.45%-45.83% 1.04B
-0.54%-4.03%-7.28%+32.69% 851M
-3.59%-6.57%-43.37%-17.58% 497M
+4.02%-5.71%-0.77% - 435M
Average -1.15%-1.37%+55.91%+41.31% 1.73B
Weighted average by Cap. -1.51%-2.65%+91.39%+86.91%

Financials

2024 2025
Net sales - 24K 27.33K 22.32K 20.48K 38.48K 2.63M 39.08K 265K 104K 1.29M 103K 100K 4.47M
Net income -3.35M -3.82M -3.12M -2.86M -5.37M -368M -5.46M -37.02M -14.46M -181M -14.33M -14.02M -625M -314K -358K -292K -268K -503K -34.43M -511K -3.47M -1.35M -16.93M -1.34M -1.31M -58.52M
Net Debt 10.46M 11.9M 9.72M 8.92M 16.76M 1.15B 17.02M 115M 45.11M 564M 44.69M 43.72M 1.95B 10.97M 12.49M 10.2M 9.36M 17.58M 1.2B 17.86M 121M 47.32M 591M 46.87M 45.86M 2.04B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
26-07-24 €0.9400 0.00% 871
26-07-23 €0.9400 0.00% 0
26-07-22 €0.9400 0.00% 0
26-07-21 €0.9400 0.00% 0
26-07-20 €0.9400 0.00% 0

Annual profits - Rate of surprise